Toward four-dimensional image-guided adaptive brachytherapy in locally recurrent endometrial cancer

被引:25
|
作者
Fokdal, Lars [1 ]
Ortoft, Gitte [2 ]
Hansen, Estrid S. [3 ]
Rohl, Lisbeth [4 ]
Pedersen, Erik Morre [4 ]
Tanderup, Kari [1 ,5 ]
Lindegaard, Jacob Christian [1 ]
机构
[1] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Gynaecol, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus C, Denmark
[4] Aarhus Univ Hosp, Dept Radiol, DK-8000 Aarhus C, Denmark
[5] Aarhus Univ, Inst Clin Med, Aarhus, Denmark
关键词
Image-guided adaptive brachytherapy; Recurrent endometrial cancer; DOSE-VOLUME PARAMETERS; ISOLATED VAGINAL RECURRENCES; ADVANCED CERVICAL-CANCER; ADJUVANT RADIOTHERAPY; RECOMMENDATIONS; CARCINOMA; SURVIVAL; THERAPY; TRIAL; ADENOCARCINOMA;
D O I
10.1016/j.brachy.2014.06.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: To evaluate clinical outcome and feasibility of a four-dimensional image-guided adaptive brachytherapy concept in patients with locally recurrent endometrial cancer. METHODS AND MATERIALS: Forty-three patients with locally recurrent endometrial cancer were included. Treatment consisted of conformal external beam radiotherapy followed by a boost using pulsed-dose-rate brachytherapy (BT). Large tumors were treated with MRI-guided interstitial BT. Small tumors were treated with CT-guided intracavitary BT. The planning aim (total external beam radiotherapy and BT) for high-risk clinical target volume was D-90 > 80 Gy, whereas constraints for organs at risk were D-2cc <= 90 Gy for bladder and D-2cc <= 70 Gy for rectum, sigmoid, and bowel in terms of equivalent dose in 2 Gy fractions. RESULTS: Median high-risk clinical target volume was 18 cm(3) (range, 0-91). D-90 was 82 Gy (range, 77-88). D-2cc to bladder, rectum, and sigmoid were 67 Gy (range, 50-81), 67 Gy (range, 51-77), and 55 Gy (range, 44-68), respectively. Median followup was 30 months (6-88). Two-year local control rate was 92% (standard error [SE], 5). Disease-free survival rate and overall survival rate was 59% (SE, 8) and 78% (SE, 7), respectively. Patients with low- to intermediate-risk for recurrence had a 2-year disease-free survival rate of 72% (SE, 9) compared with 42% (SE, 12) in patients with high risk for recurrence (p = 0.04). Late morbidity Grade 3 was recorded in 5 (12%) patients. CONCLUSIONS: Four-dimensional image-guided adaptive brachytherapy is feasible in locally recurrent endometrial cancer. Local control rate is good. Systemic control remains a problem in patients with high risk for recurrence. (C) 2014 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:554 / 561
页数:8
相关论文
共 50 条
  • [41] Tumor Shrinkage during Chemoradiation in Locally Advanced Cervical Cancer Patients: Prognostic Significance, and Impact for Image-Guided Adaptive Brachytherapy
    Schernberg, A.
    Bockel, S.
    Fumagalli, I.
    Annede, P.
    Escande, A.
    Mignot, F.
    Kissel, M.
    Morice, P.
    Deutsch, E.
    Haie-Meder, C.
    Chargari, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S220 - S221
  • [42] Effect of audio instruction on tracking errors using a four-dimensional image-guided radiotherapy system
    Nakamura, Mitsuhiro
    Sawada, Akira
    Mukumoto, Nobutaka
    Takahashi, Kunio
    Mizowaki, Takashi
    Kokubo, Masaki
    Hiraoka, Masahiro
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2013, 14 (05): : 255 - 264
  • [43] Using a deep neural network for four-dimensional CT artifact reduction in image-guided radiotherapy
    Mori, Shinichiro
    Hirai, Ryusuke
    Sakata, Yukinobu
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2019, 65 : 67 - 75
  • [44] Development of a four-dimensional image-guided radiotherapy system with a gimbaled X-ray head
    Kamino, Yuichiro
    Takayama, Kenji
    Kokubo, Masaki
    Narita, Yuichiro
    Hirai, Etsuro
    Kawawda, Noriyuki
    Mizowaki, Takashi
    Nagata, Yasushi
    Nishidai, Takehiro
    Hiraoka, Masahiro
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01): : 271 - 278
  • [45] Tumor Shrinkage During Chemoradiation in Locally Advanced Cervical Cancer Patients: Prognostic Significance, and Impact for Image-Guided Adaptive Brachytherapy
    Schernberg, Antoine
    Bockel, Sophie
    Annede, Pierre
    Fumagalli, Ingrid
    Escande, Alexandre
    Mignot, Fabien
    Kissel, Manon
    Morice, Philippe
    Bentivegna, Enrica
    Gouy, Sebastien
    Deutsch, Eric
    Haie-Meder, Christine
    Chargari, Cyrus
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (02): : 362 - 372
  • [46] Vaginal vault brachytherapy in endometrial cancer: verifying target coverage with image-guided applicator placement
    Humphrey, P.
    Cornes, P.
    Al-Booz, H.
    BRITISH JOURNAL OF RADIOLOGY, 2013, 86 (1023):
  • [47] Confirmation of Improvement in Target Dose Dosimetry for Image-guided Adaptive Brachytherapy in Cervical Cancer
    Tan, M.
    Chapman, C.
    Jones, C.
    Lalondrelle, S.
    CLINICAL ONCOLOGY, 2022, 34 : E8 - E8
  • [48] Image-guided brachytherapy for cervical cancer: A Canadian Brachytherapy Group survey
    Pavamani, Simon
    D'Souza, David P.
    Portelance, Lorraine
    Craighead, Peter S.
    Pearce, Andrew G.
    Traptow, Laurel L.
    Doll, Corinne M.
    BRACHYTHERAPY, 2011, 10 (05) : 345 - 351
  • [49] Image-guided adaptive brachytherapy dose escalation for cervix cancer via fractionation compensation
    Shaw, William
    Rae, William I. D.
    Alber, Markus L.
    BRACHYTHERAPY, 2017, 16 (03) : 534 - 546
  • [50] Local failure in cervical cancer patients after MR image-guided adaptive brachytherapy
    Schmid, M.
    Kirisits, C.
    Tanderup, K.
    Haie-Meder, C.
    Fokdal, L.
    Sturdza, A.
    Hoskin, P.
    Mahantshetty, U.
    Segedin, B.
    Bruheim, K.
    Huang, F.
    Rai, B.
    Cooper, R.
    Van der Steen-Banasik, E.
    Van Limbergen, E.
    Pieters, B.
    Tan, L. T.
    Nout, R.
    De Leeuw, A. A. C.
    Nesvacil, N.
    Jurgenliemk-Schulz, I.
    Lindegaard, J. C.
    Poetter, R.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S1100 - S1101